< Back to previous page
Researcher
Peter Carmeliet
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Cancer biology
- Disciplines (KU Leuven):Cardiac and vascular medicine
- See also: Peter Carmeliet (Flanders Institute for Biotechnology)
Affiliations
- Laboratory of Angiogenesis and Vascular Metabolism (VIB-KU Leuven) (Division)
Responsible
From1 Jan 2012 → Today - Carmeliet Lab (Research group)
Responsible
From1 Jan 2017 → Today - Laboratory of Angiogenesis and Vascular Metabolism (VIB-KU Leuven) (Division)
Member
From1 Jan 2012 → Today - Centre for Molecular and Vascular Biology (Division)
Member
From1 Oct 1999 → 30 Sep 2005
Projects
21 - 30 of 110
- Development of a new point-of-care COVID-19 screening using exhaled-breath volatilome analysis.From1 Apr 2020 → 31 Mar 2021Funding: IOF - technology validation in lab
- The tumor endothelium: an overlooked target to improve immunotherapy?From1 Jan 2020 → 31 Dec 2023Funding: FWO research project (including WEAVE projects)
- Tumor endothelial cell metabolism, a target for anti-angiogenic & immunotherapy.From1 Oct 2019 → 31 Jul 2021Funding: FWO fellowships
- ScRNA-seq analysis of tumor endothelial cells and cancer cells to unravel vessel co-option, a resistance mechanism to anti-angiogenic therapyFrom1 Sep 2019 → TodayFunding: FWO fellowships, Foundations, funds and other with scientific goal
- Tuning endothelial cells into ‘professional’ antigen presenting endothelial cells by using lipid nanoparticlesFrom1 Mar 2019 → 24 May 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- Development of PFKFB3 blockers for anti-angiogenic tumor therapyFrom1 Jan 2019 → 31 Dec 2021Funding: International Cooperation and Mobility
- Unravelling the role of ketone body oxidation in lymphagiogenesisFrom1 Oct 2018 → 1 Oct 2022Funding: FWO fellowships
- Mass cytometry by time-of-flight: next-generation flow cytometry for multiplexed single cell analysisFrom1 May 2018 → 30 Apr 2022Funding: FWO Medium Size Research Infrastructure
- Replacement and upgrade of electronics and gradients for preclinical magnetic resonance imagingFrom1 May 2018 → 30 Apr 2022Funding: FWO Medium Size Research Infrastructure
- Single cell analysis of tumor endothelial cells during vessel co-optionFrom24 Apr 2018 → 30 Sep 2018Funding: Own budget, for example: patrimony, inscription fees, gifts
Publications
1 - 10 of 587
- Fatty acid oxidation fuels natural killer cell responses against infection and cancer.(2024)
Authors: Peter Carmeliet
Pages: e231925412 - Targeting hypoxia-inducible factors: therapeutic opportunities and challenges(2024)
Authors: Peter Carmeliet
- Editorial Expression of Concern: The netrin receptor UNC5B mediates guidance events controlling morphogenesis of the vascular system.(2024)
Authors: Peter Carmeliet
Pages: E12 - The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression (vol 23, pg 1476, 2018)(2023)
Authors: Peter Carmeliet
- Detailed protocol for a corneal thermal cauterization-based (lymph-)angiogenesis assay in mice(2023)
Authors: Anh-Co Truong, Koen Veys, Mieke Dewerchin, Peter Carmeliet
- Glucose Controls Glucagon Secretion by Regulating Fatty Acid Oxidation in Pancreatic α-Cells(2023)
Authors: Peter Carmeliet
Pages: 1446 - 1459 - Renal Endothelial Cell Metabolism in Health and Acute Kidney Injury: a window for therapeutic opportunities(2023)
Authors: Mila Borri, Peter Carmeliet, Guy Eelen, Sébastien Dumas
- VEGF-B prevents excessive angiogenesis by inhibiting FGF2/FGFR1 pathway(2023)
Authors: Mieke Dewerchin, Peter Carmeliet
- PARTIAL MYELOID INHIBITION OF KEY GLYCOLYTIC ENZYME PFKFB3 INCREASES HEPATIC STEATOSIS AND INFLAMMATION, BUT DOES NOT AFFECT ATHEROSCLEROSIS(2023)
Authors: Peter Carmeliet
- Understanding tumour endothelial cell heterogeneity and function from single-cell omics(2023)
Authors: Peter Carmeliet
Pages: 544 - 564
Patents
1 - 10 of 10
- Carnitine palmitoyltransferase 1 inhibitors for inhibition of pathological angiogenesis (Inventor)
- Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor (Inventor)
- Inhibition of plgf to treat philadelphia chromosome positive leukemia (Inventor)
- Means and methods for treating lung hypoplasia (Inventor)
- Use of VEGF and homologues to treat neuron disorders (Inventor)
- Novel anti-PLGF antibody (Inventor)
- Anti-angiogenic therapy (Inventor)
- Responsiveness to angiogenesis inhibitors (Inventor)
- CARNITINE PALMITOYLTRANSFERASE 1 INHIBITORS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS (Inventor)
- GLUTAMINE SYNTHETASE INHIBITORS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS (Inventor)